{"id":17113,"date":"2026-03-27T21:21:42","date_gmt":"2026-03-27T20:21:42","guid":{"rendered":"https:\/\/vascular.hu\/holding\/?p=17113"},"modified":"2026-03-27T21:22:24","modified_gmt":"2026-03-27T20:22:24","slug":"geneplanet-acquires-new-era-genetics-strengthening-presence-in-central-europe","status":"publish","type":"post","link":"https:\/\/vascular.hu\/holding\/geneplanet-acquires-new-era-genetics-strengthening-presence-in-central-europe\/","title":{"rendered":"GenePlanet acquires New Era Genetics, strengthening presence in Central Europe"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Ljubljana \/ Budapest \u2013 20.2.2026 \u2013 GenePlanet d.o.o., a leading European genomics company specialising in genetic testing, has&nbsp;<strong>acquired New Era Genetics<\/strong>, a Hungarian genetic testing company based in Budapest, from Vascular Group.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The acquisition represents a strategic step in GenePlanet\u2019s continued expansion across Central and Eastern Europe and strengthens its local presence, laboratory capabilities and partnerships in Hungary.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">By joining the GenePlanet group, New Era Genetics becomes part of a global company, supported by GenePlanet\u2019s proven expertise, scalable platforms and European laboratory infrastructure.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThis acquisition aligns with our long-term strategy of building strong local hubs supported by central scientific expertise and technology,\u201d said<strong>&nbsp;Sebastjan Gergeta, Chief Strategy Officer of GenePlanet.&nbsp;<\/strong>\u201cHungary is an important market for us, and New Era Genetics is a natural fit in terms of quality standards, medical focus and values.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Together, the companies now offer a broader portfolio of genetic solutions for healthcare professionals and patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Zolt\u00e1n Merhala, Director of New Era Genetics,<\/strong>&nbsp;added: \u201cThis step strengthens our long-term stability and gives us access to additional expertise and operational resources, allowing us to further develop our services.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">With this acquisition, GenePlanet further strengthens its position as a leading European provider of genetic testing, now operating in more than 50 countries and offering an increasingly broad spectrum of high-quality, clinically relevant genetic solutions.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"281\" height=\"375\" src=\"https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2026\/03\/new_era-linkedin-image2-e1771579966740.jpg\" alt=\"\" class=\"wp-image-17115\" srcset=\"https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2026\/03\/new_era-linkedin-image2-e1771579966740.jpg 281w, https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2026\/03\/new_era-linkedin-image2-e1771579966740-225x300.jpg 225w\" sizes=\"(max-width: 281px) 100vw, 281px\" \/><\/figure>\n<\/div>\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" width=\"1024\" height=\"768\" src=\"https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2026\/03\/new_era-linkedin-image1-1024x768-1.jpg\" alt=\"\" class=\"wp-image-17114\" style=\"width:415px;height:auto\" srcset=\"https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2026\/03\/new_era-linkedin-image1-1024x768-1.jpg 1024w, https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2026\/03\/new_era-linkedin-image1-1024x768-1-300x225.jpg 300w, https:\/\/vascular.hu\/holding\/wp-content\/uploads\/2026\/03\/new_era-linkedin-image1-1024x768-1-768x576.jpg 768w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About GenePlanet<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>GenePlanet d.o.o.<\/strong>&nbsp;is a European genomics company specialising in preventive and medical genetic testing. With more than 18 years of experience, GenePlanet operates across more than 50 countries worldwide, supporting over 5.000 healthcare professionals, partners and patients with clinically relevant genetic insights. The company combines EU-based laboratory infrastructure, advanced bioinformatics and strict data protection standards (ISO 27001).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About New Era Genetics<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>New Era Genetics<\/strong>&nbsp;is a Hungary-based genetic testing company focused on delivering genetic solutions to healthcare professionals and patients. The company works closely with medical partners to support preventive care, diagnostics and informed clinical decision-making within the Hungarian healthcare system.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>About Vascular Group<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Vascular Group<\/strong>&nbsp;is a Hungary-based life sciences and healthcare innovation group focused on the identification, validation, and commercialization of high-impact biomedical and healthcare technologies. Through its integrated network of research, clinical, and investment platforms, the group supports the growth of globally competitive health innovation initiatives.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ljubljana \/ Budapest \u2013 20.2.2026 \u2013 GenePlanet d.o.o., a leading European genomics company specialising in genetic testing, has&nbsp;acquired New Era Genetics, a Hungarian genetic testing company based in Budapest, from Vascular Group. The acquisition represents a strategic step in GenePlanet\u2019s continued expansion across Central and Eastern Europe and strengthens its local presence, laboratory capabilities and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[81],"tags":[],"class_list":["post-17113","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts\/17113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/comments?post=17113"}],"version-history":[{"count":1,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts\/17113\/revisions"}],"predecessor-version":[{"id":17116,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/posts\/17113\/revisions\/17116"}],"wp:attachment":[{"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/media?parent=17113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/categories?post=17113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vascular.hu\/holding\/wp-json\/wp\/v2\/tags?post=17113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}